Bristol Myers Squibb receives European approval for subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Thursday, May 29, 2025, 15:0 ...

Triumvira is taking a different approach with its autologous Claudin 18.2-directed T cell therapy for gastric cancer, which is still in preclinical development.

CLDN18.2 is a transmembrane protein expressed in approximately 38% of advanced gastric cancer cases and is not generally seen in healthy tissues, making it almost completely tumour-specific ...

Dogs share our homes, our habits and sometimes, our diseases. Gastric cancer is rare in dogs, but when it does strike, it ...

Patients with newly diagnosed gastric or gastroesophageal junction (GEJ) cancer who received the PD-L1 inhibitor durvalumab ...

Gastric cancer, the fifth most common malignancy worldwide ... of drugs targeting new molecular targets such as claudin 18.2 (CLDN18.2) and fibroblast growth factor receptor 2 (FGFR2).

For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, ...

Adding durvalumab to perioperative FLOT improved EFS in patients with resectable gastric or GEJ cancer in the MATTERHORN ...

AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to ...

Over the past 2 decades, detection of early-stage gastric cancer has increased by more than 50%. This finding may be attributed to improved endoscopic imaging and increased utilization of upper ...

(D) Cancer cells show partial membrane staining with weak (1+) intensity (arrow). (E) Gastric adenocarcinoma, biopsy from the stomach. (F) Tumor cells have complete or partial membrane staining with ...